Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30

$267.07+7.79 (+3.00%)

Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –

Ascendis Pharma A/S ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	€225.03M	–
Q1 FY2026	Mar 31, 2026	€29.03M	–
Q2 FY2025	Jun 30, 2025	-€48.64M	–
Q1 FY2025	Mar 31, 2025	-€99.67M	–

Parsed from the XBRL in Ascendis Pharma A/S's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ASND.

Revenue growth113.4% · median 25.9%

Gross margin91.3% · median 96.3%

Operating margin25.4% · median -20.5%

Net margin70.8% · median -13.9%

Advertisement
300 × 250

See a number that looks wrong?